Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $8 million, down 3% from $8.2 million in Q4 2024, but at the high end of the pre-announced range of $7.8 million-$8 million [6] - Full year 2025 revenue was $28.5 million, down 7% from $30.8 million in 2024 [6] - Non-GAAP gross margin for Q4 2025 was 43%, up from 42% a year ago; for the full year, it was 47%, up from 35% in 2024, reflecting a 1,200 basis points improvement [7][8] - Non-GAAP operating expenses for Q4 2025 were $9.7 million, down 9% year-over-year; for the full year, they were $36.6 million, down 47% from $68.9 million in 2024 [9] Business Line Data and Key Metrics Changes - Sold 7,554 nanochannel array flow cells in Q4 2025, down 6% year-over-year; full year sales were 30,171 flow cells, down just 0.4% [6][7] - Consumables and software revenue decreased by 1% to $4.8 million in Q4, driven by a 22% decline in software revenue, offsetting 8% growth in consumables [12] - Consumables and software revenue grew for the full year from $19 million to $20.4 million, representing 7% growth [13] Market Data and Key Metrics Changes - The company focused on routine use customers, who accounted for about 83% of OGM consumables revenue in 2025 [15] - Routine use customers, representing about 30-40% of total customers, operated approximately 175 systems or 45% of the global installed base [14] - The average revenue per routine use customer in 2025 was about $89,000, double the average per customer across the entire global installed base [15] Company Strategy and Development Direction - The company shifted its strategy in September 2024 to focus on profitable growth from high volume users and selective customer acquisition [10] - Four strategic pillars were established: support the installed base, increase utilization of optical genome mapping, build support for reimbursement, and improve profitability and scalability [11] - The company aims to enhance customer workflows and expand the use of its products through software upgrades and automation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong outlook for 2026, initiating revenue guidance of $30 million-$33 million, representing 5%-16% growth over 2025 [26] - The establishment of a second Category I CPT code for OGM and a 47% increase in payment determination for existing codes were highlighted as significant catalysts for growth [20][32] - Management noted that the community is becoming advocates for OGM, indicating a shift in market dynamics [21] Other Important Information - The company ended 2025 with $29.6 million in cash equivalents and available-for-sale securities, with expectations for a cash runway extending into 2027 [9] - The Bionano Symposium 2026 had over 1,250 registrants from 73 countries, showcasing significant community engagement and interest in OGM [23] Q&A Session Summary Question: Expectations for new OGM systems installations in 2026 - Management expects installations to be comparable to the previous year but did not provide specific guidance [28] Question: Sales expectations for nanochannel array flow cells in 2026 - Management indicated that consumables volume is expected to track with revenue growth, despite supply constraints affecting sales [29][30] Question: Revenue growth drivers for 2026 - Management emphasized the importance of routine users and the impact of increased reimbursement rates as key growth catalysts [31][32]

Financial Data and Key Metrics Changes - Talphera reported a cash and investments balance of $20.4 million as of December 31, 2025, which, along with remaining financing tranches, is expected to provide a runway through potential FDA approval of Niyad next year [5] - The company achieved gross proceeds of $4.1 million from the closing of the third tranche of financing triggered by reaching the 50% enrollment milestone in the Nephro CRRT study [4] Business Line Data and Key Metrics Changes - The Nephro CRRT study is progressing well, with the company reaching the 50% enrollment milestone [4] - The primary endpoint of the study is measured at 24 hours, indicating a quick turnaround of data is expected once patient enrollment is completed [5] Market Data and Key Metrics Changes - The incidence rates of acute kidney injury (AKI) severe enough to require dialysis, particularly continuous renal replacement therapy (CRRT), are increasing, indicating a growing market for Talphera's products [28] - The chronic dialysis population in the U.S. is stabilizing, while the ICU population requiring CRRT is growing, suggesting a shift in market dynamics [27] Company Strategy and Development Direction - Talphera aims to address the unmet need for anticoagulation in CRRT circuits with nafamostat, which is being studied in the Nephro CRRT registrational study [3] - The company expects to complete enrollment of the NEPHRO CRRT study later this year and file the PMA within about three months after study completion [5] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increasing complexity of patients in ICUs and the corresponding rise in acute kidney injury cases, which is expected to dominate nephrology practice in the future [28] - The management expressed optimism about the potential for nafamostat to fill a significant gap in current anticoagulation options for CRRT [3] Other Important Information - The company is focused on continuous renal replacement therapy (CRRT), which is a critical treatment for patients in intensive care units [6] - There are significant challenges in managing anticoagulation during CRRT, with current options like heparin and citrate having limitations [43][55] Q&A Session Summary Question: What are the key differences between CRRT and intermittent hemodialysis? - CRRT is used for critically ill patients requiring gentle, continuous dialysis, while intermittent hemodialysis is for more stable patients [20][23] Question: What trends are being observed in the incidence rates of end-stage kidney disease versus acute kidney injury? - The chronic dialysis population is stabilizing, while acute kidney injury cases are increasing, particularly in ICU settings [27][28] Question: What are the implications of filter clotting in CRRT? - Clotting leads to interruptions in therapy, increased nursing workload, and potential blood loss, which can be detrimental to critically ill patients [48][51] Question: What anticoagulation strategies are being used? - Citrate is preferred in some institutions due to its efficacy, but it requires careful monitoring and can be complex to manage [57][134]

Financial Data and Key Metrics Changes - The company announced Q4 and full-year financial results, achieving a gross proceeds of $4.1 million from the third tranche of financing triggered by reaching the 50% enrollment milestone in the Nephro CRRT study [5][6]. - As of December 31, the company had cash and investments totaling $20.4 million, which, along with remaining tranches, is expected to provide a runway through a potential FDA approval of Niyad next year [6]. Business Line Data and Key Metrics Changes - The Nephro CRRT study is progressing well, with expectations to complete enrollment later this year and file the PMA within about three months after study completion [6]. Market Data and Key Metrics Changes - The incidence rates of acute kidney injury (AKI) severe enough to require dialysis, particularly continuous renal replacement therapy (CRRT), are increasing, driven by factors such as septic shock and the growing complexity of ICU patients [29][30][40]. Company Strategy and Development Direction - The company aims to address the unmet need for anticoagulation in CRRT circuits, with a focus on nafamostat as a potential solution [3][5]. - The management highlighted the importance of continuous renal replacement therapy in the ICU setting, emphasizing the need for effective anticoagulation strategies to prevent filter clotting [7][44]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the CRRT market, noting that the patient population requiring such therapies is expected to continue increasing due to the aging population and rising chronic kidney disease rates [29][33]. - The management acknowledged the challenges associated with current anticoagulation methods, particularly heparin, and the need for improved alternatives like citrate, despite its complexities [56][101]. Other Important Information - The company is actively involved in discussions about the complexities and challenges of using citrate as an anticoagulant, which has implications for nursing staff and patient safety [141][160]. - The management noted logistical challenges related to the storage and administration of citrate solutions, which can complicate treatment protocols [164][171]. Q&A Session Summary Question: What are the key differences between CRRT and intermittent hemodialysis? - CRRT is used for critically ill patients in the ICU, providing continuous and gentler dialysis, while intermittent hemodialysis is typically for more stable outpatient chronic dialysis patients [21][24]. Question: Are there any trends in the incidence rates of end-stage kidney disease versus acute kidney injury? - The chronic dialysis population is stabilizing, while the incidence of acute kidney injury is increasing, particularly in ICU settings [28][30]. Question: What anticoagulation strategies are being used? - The use of citrate is becoming more common, but it presents challenges in monitoring and administration, while heparin is often avoided due to its inefficacy and bleeding risks [56][101][128].

Financial Data and Key Metrics Changes - The company announced Q4 and full-year financial results, achieving a gross proceeds of $4.1 million from the third tranche of financing triggered by reaching the 50% enrollment milestone in the Nephro CRRT study [3][4] - As of December 31, the company had cash and investments totaling $20.4 million, which, along with remaining tranches, is expected to provide a runway through potential FDA approval of Niyad next year [4] Business Line Data and Key Metrics Changes - The Nephro CRRT study is progressing well, with expectations to complete enrollment later this year and file the PMA within about three months after study completion [4] Market Data and Key Metrics Changes - Continuous renal replacement therapy (CRRT) is increasingly recognized as a critical treatment modality for patients in intensive care units, with a growing incidence of acute kidney injury requiring such interventions [26][27] Company Strategy and Development Direction - The company is focused on addressing unmet needs in anticoagulation for CRRT, with management emphasizing the importance of effective anticoagulants to prevent filter clotting during treatment [5][6] - The management is aware of the complexities and challenges associated with current anticoagulation methods, such as heparin and citrate, and is exploring better options for patient safety and efficacy [8][9] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increasing complexity of patients in ICUs and the rising incidence of acute kidney injury, suggesting that the demand for CRRT will continue to grow [27][30] - There is a recognition that the chronic dialysis population is stabilizing, while the acute kidney injury population is expanding, indicating a shift in treatment focus [25][28] Other Important Information - The company is actively engaging with key experts in the field to enhance understanding and management of CRRT, which is crucial for improving patient outcomes [2][6] Q&A Session Summary Question: What are the key differences between CRRT and intermittent hemodialysis? - CRRT is a continuous, gentle form of dialysis for critically ill patients, while intermittent hemodialysis is typically for more stable patients [20][22] Question: Are there any trends in the incidence rates of end-stage kidney disease versus acute kidney injury? - The chronic dialysis population is stabilizing, while the incidence of acute kidney injury is increasing, particularly in ICU settings [25][27] Question: What are the challenges associated with using citrate as an anticoagulant? - Citrate requires intensive monitoring and can lead to metabolic disturbances, making its use complex and burdensome for nursing staff [140][156] Question: What is the current status of heparin use in CRRT? - Heparin is still used but is not favored due to its unpredictability and systemic anticoagulation risks; citrate is preferred despite its complexities [101][123] Question: What is the ideal profile for an anticoagulant in CRRT? - An ideal anticoagulant would be effective, safe for high-risk patients, and remain confined to the circuit without systemic effects [210][218]

Financial Data and Key Metrics Changes - In 2025, Lithium Argentina achieved production of over 34,000 tons, reaching the high end of guidance, with fourth quarter production at 97% capacity [3] - Fourth quarter operating cash costs were approximately $5,600 per ton, a 30% decline from over $8,000 per ton in Q1 2024 [6][7] - Adjusted EBITDA for Cauchará-Olaroz was $56 million despite a low lithium price environment [5] Business Line Data and Key Metrics Changes - Cauchará-Olaroz's operational performance improved significantly, achieving close to nameplate capacity with production of approximately 9,700 tons in Q4 [4] - The company expects production in 2026 to be in the range of 35,000-40,000 tons of lithium carbonate, focusing on sustaining stable operations [9] Market Data and Key Metrics Changes - Since mid-2025, there has been a significant recovery in lithium prices, driven by increasing demand from electric vehicles and energy storage systems [8] - The company anticipates that energy storage systems will continue to support lithium prices, with expectations for pricing to remain volatile but stable [39] Company Strategy and Development Direction - The company aims to scale production from approximately 40,000 tons to over 200,000 tons of lithium chemicals, leveraging existing operations and cash flow from stage one [12][15] - The company is advancing the stage two expansion plan of 45,000 tons at Cauchará-Olaroz and progressing the PPG project, targeting a total of 150,000 tons [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational resilience against external factors, noting minimal impact from geopolitical events on operations [27] - The company is well-positioned to capitalize on the growing demand for lithium, particularly from energy storage systems, and expects to generate significant EBITDA under various price scenarios [11][39] Other Important Information - The company completed a $130 million debt facility with Ganfeng, enhancing balance sheet flexibility [12][41] - The resource base at Cauchará-Olaroz was updated, showing a 42% increase in total measured and indicated resources, positioning it among the largest lithium brine assets globally [13] Q&A Session Summary Question: Cash cost expectations for 2026 - Management indicated that cash costs are expected to remain below $6,000 per ton, with Q1 likely settling around $5,600 per ton [20][21] Question: Pricing expectations for Q1 - Management explained that pricing is based on market prices for battery-quality lithium carbonate outside of China, with adjustments for quality [22][23] Question: Impact of global market volatility - Management noted that they are monitoring global market conditions but have not seen material impacts on operations, with strong demand from China continuing [26][27] Question: Financing environment for expansion - Management highlighted a strong cash position and the potential for debt financing for stage two, while also exploring equity financing options for the PPG project [41][43] Question: Competitive advantage in cost structure - Management acknowledged that while Argentina has potential for low-cost production, Lithium Argentina's unique execution and resource quality provide a competitive edge [45][47] Question: Sodium battery evolution and impact on lithium demand - Management stated that while sodium batteries are a topic of discussion, they do not view them as a material threat to lithium demand at current price levels [50][51]

Financial Performance - Revenue increased by 46% to $267 million, gross profit rose by 78% to $137 million, EBITDA surged by 100% to just over $125 million, and profit after tax jumped by 200% to $67 million [3][12][22] - Free cash flow reached $62 million, up 483% year-over-year, with earnings per share at $2.83, also up over 200% [13][22] Business Line Performance - Blanket Mine produced 76,000 ounces of gold and sold 77,000 ounces, while Bilboes oxide operation produced and sold 1,683 ounces, totaling 79,000 ounces [11] - On-mine costs increased by 19%, reflecting restricted access to higher-grade areas and inflationary pressures [11][12] Market Data - The royalty increased to $13.5 million due to higher revenue, with a new royalty rate applied for ounces sold over $5,000 [19] - The company reported a decrease in net foreign exchange losses from $9.7 million to $3.3 million, indicating improved currency conditions [20] Company Strategy and Industry Competition - The company aims to leverage the strong gold price to invest in Blanket's projects and mitigate input cost pressures while advancing the Bilboes project [56] - A strategic focus on safety and operational reliability was emphasized following a fatal incident, with plans to enhance risk management and embed a zero harm culture [6][56] Management Commentary on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential of the Bilboes project and ongoing exploration at Motapa, which is expected to yield significant results [56][45] - The company is committed to becoming a multi-asset Zimbabwe-focused gold producer, balancing growth and shareholder returns [31][56] Other Important Information - The company successfully completed a $150 million convertible note offering, enhancing its cash position for future developments [25] - Capital expenditures for 2026 are projected at $178.9 million, with significant allocations for the Bilboes project and sustaining capital [29][30] Q&A Session Summary Question: What is the maturity of the convertible bond? - The maturity is seven years, designed to mature outside the timing of the scheduled repayment of the project finance [61][62] Question: What is the capital gains rate on the solar plant sale? - The capital gains tax ended up being $2 million, with a combination of total capital gain and profit elements [69] Question: Will further investment in solar facilities become a higher priority? - No, the current strategy does not prioritize further solar investments due to reliability issues with solar power in the region [87] Question: What is the sustaining capital guidance for 2026? - The company is reviewing the all-in sustaining cost guidance, which remains between $2,100 and $2,300 per ounce [92] Question: What is the status of the derivative loss recorded? - The derivative loss is related to the put options purchased, which create a floor price for cash flows [97][99] Question: What is the minimum cash requirement for operations? - A healthy cash position would be between $30 million and $50 million to ensure operational liquidity [123]

Financial Data and Key Metrics Changes - In 2025, Lithium Argentina achieved production of over 34,000 tons, reaching the high end of guidance, with fourth quarter production at 97% capacity [3] - Fourth quarter operating cash costs were approximately $5,600 per ton, a 30% decline from over $8,000 per ton in Q1 2024 [5][6] - Adjusted EBITDA for Cauchará-Olaroz was $56 million despite a low lithium price environment [5] - The company forecasts long-term costs at full capacity to be around $5,400 per ton, down from $6,500 a year ago, representing a 17% reduction [6] Business Line Data and Key Metrics Changes - Cauchará-Olaroz demonstrated strong operational performance, achieving close to nameplate capacity with production of approximately 9,700 tons in Q4 [4] - The operation distributed $85 million in cash, with $42 million attributed to Lithium Argentina [3][11] Market Data and Key Metrics Changes - Since mid-2025, there has been a significant recovery in lithium prices, driven by increasing demand from electric vehicles and energy storage systems [8] - The current market price for lithium carbonate is about $20,000 per ton, with expectations for production in 2026 to support significant EBITDA under various price scenarios [9][11] Company Strategy and Development Direction - The company aims to scale production from approximately 40,000 tons to over 200,000 tons of lithium chemicals, leveraging the existing operations at Cauchará-Olaroz [12][16] - The expansion plan includes advancing stage two at Cauchará-Olaroz and developing PPG, targeting a total of 150,000 tons of lithium production [14][16] - The company is focused on de-risking growth through RIGI approvals and financing plans with Ganfeng [15][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational resilience against external factors, noting minimal impact from geopolitical events on operations [27] - The company is well-positioned to capitalize on the growing demand for lithium, particularly from energy storage systems [8][16] - Management highlighted a supportive investment environment in Argentina, with over $70 billion in investment applications submitted under the RIGI program [13] Other Important Information - The company completed a $130 million debt facility with Ganfeng, enhancing balance sheet flexibility [12][42] - The resource base at Cauchará-Olaroz has increased by approximately 42%, positioning it among the largest lithium brine assets globally [13] Q&A Session Summary Question: Cash cost expectations for 2026 - Management indicated that cash costs are expected to remain below $6,000 per ton, with $5,600 being a good indication for the year [20][21] Question: Realized price expectations for Q1 - Management explained that pricing is based on market prices for battery-quality lithium carbonate outside of China, with adjustments for quality [22][23] Question: Impact of global market volatility - Management noted that they are monitoring global market conditions but have not seen material impacts on operations [26][27] Question: Financing environment for expansion - Management expressed confidence in their ability to finance growth without requiring equity contributions from shareholders [42][44] Question: Competitive advantage in cost structure - Management acknowledged that while Argentina has potential for low-cost production, Lithium Argentina's unique resource quality and operational execution provide a competitive edge [46][47] Question: Stage two bottlenecking opportunities - Management indicated that further investment could push production above 40,000 tons, but current planning is focused on RIGI applications [48][49] Question: Evolution of sodium batteries - Management believes that while sodium batteries are a legitimate risk if lithium prices spike, they do not see it as a material threat at current price levels [50][52]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with a projected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism of action and promising preclinical results [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients who have run out of standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue to the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28][29] Question: Enthusiasm from principal investigators for GLIX1 trial - There is significant enthusiasm from investigators regarding GLIX1's novel mechanism of action and preclinical results, with eagerness to initiate the study [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway, but no interim readouts expected due to the study's blinded nature [44][46] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients, typically having exhausted standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [18] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [19] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [20] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [20] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][20] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [12] - The company continues to support the development of motixafortide in pancreatic cancer, with a phase IIb clinical trial showing accelerated enrollment [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU [8] - The unmet need in glioblastoma treatment is significant, with current therapies showing limited advancements since 2005 [7] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma and other cancers, highlighting the enthusiasm from clinical investigators [38] - The company is well-positioned to drive innovation in challenging cancer types and is focused on maximizing the value of GLIX1 [56] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [16] - The company remains a lean organization following the shutdown of U.S. commercialization operations, concentrating on development [12] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [27][28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism and promising preclinical results [38] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the study are recurrent or progressed GBM patients, having run out of standard care options [46] Question: Measurement of blood-brain barrier penetration in the study - While biopsies may be taken, the study is not designed to assess blood-brain barrier penetration as a primary measure [50] Question: Ayrmid's guidance on expected sales - Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [51]